Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]
, 2017 Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N +15 more
core +1 more source
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]
, 2015 Importance Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.
Cooper, James +24 more
core +1 more source
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study [PDF]
, 2017 Background and aims Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV ...
Balslev, Ulla +16 more
core +7 more sources
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
Gut and Liver, 2018 Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki +11 more
doaj +1 more source
Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV [PDF]
Advanced Pharmaceutical Bulletin, 2020 Purpose: Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced.
Mohammad Hossein Somi +3 more
doaj +1 more source
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C [PDF]
, 2013 Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever use of an interferon‐free, all oral regimen in a liver ...
Appelman, H. +6 more
core +1 more source
Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]
, 2017 Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia +13 more
core +1 more source
Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek [PDF]
, 2015 Absztrakt A krónikus C-vírus hepatitis kezelés nélkül 15–25 év alatt májzsugort, májelégtelenséget, májrákot okozhat.
Halász, Tünde +3 more
core +1 more source
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]
, 2016 [Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S. +27 more
core +2 more sources
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
Hepatology Research, EarlyView.ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki +10 more
wiley +1 more source